News

Where Will Eli Lilly Be in 10 Years? 1 Clue: Its Next Potential Blockbuster Just Beat Ozempic Head-to-Head

NASDAQ

Key PointsRetatrutide beat Ozempic in a head-to-head trial, highlighting Lilly’s dominance in its core area.

Read the full Veytics brief

We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.